FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, specifically to recombinant production of fused proteins of Roundabout 2 receptor (hereinafter – ROBO2); it can be used in medicine for the treatment of a kidney disease. Fused ROBO2-Fc proteins contain Fc domain and part of an extracellular ROBO2 domain consisting of two immunoglobulin-like domains (Ig1 and Ig2) and two intradomain linkers (Ig1-Ig2 linker and Ig2-Ig3 linker), while the specified protein is deprived of three repeats of a fibronectin III type.
EFFECT: invention allows for obtainment of recombinant ROBO2-Fc proteins, which are capable of binding to slit guidance ligand SLIT2 and inhibiting ROBO2-dependent activity of SLIT2.
37 cl, 16 dwg, 24 tbl, 10 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS OF TREATING TISSUE CALCIFICATION | 2015 |
|
RU2770698C2 |
| RECOMBINANT PROTEINS WITH CCN DOMAINS AND FUSION PROTEINS | 2020 |
|
RU2825102C2 |
| ADAM9-BINDING MOLECULES AND THEIR APPLICATION METHODS | 2017 |
|
RU2783619C2 |
| BISPECIFIC ANTIBODY AGAINST CD3E/BCMA AND ITS USE | 2019 |
|
RU2800164C2 |
| PROTEINS BINDING NKG2D, CD16 AND TUMOUR-ASSOCIATED ANTIGEN | 2018 |
|
RU2816716C2 |
| CD33, NKG2D AND CD16 BINDING PROTEINS | 2018 |
|
RU2820603C2 |
| FUSED POLYPEPTIDE WITH ANTI-CANCER ACTIVITY | 2016 |
|
RU2754466C2 |
| CSF1R-BASED CHIMERIC PROTEINS | 2018 |
|
RU2792239C2 |
| COMPOSITIONS FOR THE TREATMENT OF PATHOLOGICAL CONDITIONS OF CALCIFICATION AND THEIR APPLICATION METHODS | 2016 |
|
RU2757417C2 |
| ANTIBODIES TARGETING C5aR | 2020 |
|
RU2823245C2 |
